Objective: This study aimed to identify the hormonal receptor status in uterine adenosarcoma (AS) and uterine AS with sarcomatous overgrowth (AS + SO), including those with high-grade histologic features (nuclear pleomorphism, atypical mitoses, necrosis), with or without heterologous elements. Estrogen receptor (ER) status, including estrogen receptor > (ER>), estrogen receptor A (ERA), and G proteinYcoupled estrogen receptor (GPER), and progesterone receptor (PgR) status were examined. Methods: From August 2001 to November 2013, 11 patients with histologic diagnosis of uterine AS were identified. Tumor tissue sections were stained for ER>, ERA, GPER, and PgR and examined both for percentage of overall cells stained and for intensity of staining. Descriptive statistics were calculated using clinicopathologic data abstracted from the medical record. Results: Eight cases of AS and 3 cases of AS with high-grade features were identified. Seven of 8 tumor samples of AS showed strong or moderate intensity immunostaining for ER>; all AS + SO tumor samples showed minimal to no immunoreactivity for ER>. There was a significant decrease in ER> H scores in high-grade tumors when compared with AS (P = 0.01). Lower PgR H scores were observed in high-grade tumors compared with those in AS (P = 0.04). Estrogen receptor A immunostaining was variable, and GPER immunostaining was absent in the majority of tumor samples. Conclusions: Higher expression of ER> and PgR was observed in AS when compared with those with AS + SO and high-grade features. Both tumor subtypes showed similar levels of ERA and GPER expression, although significant differences in ERA and GPER expression were not detected. In contrast to our previous findings in uterine carcinosarcoma, ERs ERA and GPER do not seem to play a significant role in AS in this study.
diagnosed at an early stage, these tumors can be managed surgically and are generally associated with a favorable prognosis. Conversely, ASs with sarcomatous overgrowth (ASs + SO) contain more than 25% pure sarcoma, behave in a more aggressive fashion, and are associated with worse clinical outcomes.
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Adenosarcomas with sarcomatous overgrowth often display high-grade histopathologic features with marked cytologic atypia, with or without heterologous elements. The immunoprofiling of AS has revealed a greater prevalence of estrogen receptor > (ER>) and progesterone receptor (PgR) expression when compared with AS + SO. 9 In contrast, ASs + SO display a loss of ER/PgR expression, an increased Ki-67 proliferation index, and loss of CD10 expression. 10 Expression of different subtypes of estrogen receptor (ER) in various tumors has been described. For example, in ovarian carcinoma, loss of estrogen receptor A (ERA) expression, a classic nuclear ER homolog of ER>, has been linked to the development of the disease. 11 Recently, expression of an ERA isoform localized to the cytoplasm had been described to be associated with a decreased overall survival and increasing rates of chemoresistance. 12 An additional ER of the 7-transmembrane G proteinYcoupled receptor family, the G proteinYcoupled ER (GPER), reportedly interacts with estrogen independently of the classic receptors.
13Y16 G proteinYcoupled ER has been shown to have complex effects in different tumor types with both stimulatory and inhibitory actions. Interestingly, GPER is stimulated by several different ligands in addition to estrogen, including the antiestrogens such as tamoxifen and raloxifene. 13, 17 In breast cancer, both its overexpression and down-regulation have been linked to advanced disease and poor prognosis. 18 In endometrial cancer, GPER expression has been inversely associated with the expression of ER>. 19 Clinically, the increased expression of GPER has been linked to aggressive uterine tumors and shown to be associated with advanced-stage disease. 20 The variable prognosis in patients with uterine AS is dependent on stage at diagnosis and the presence of sarcomatous overgrowth and/or heterologous elements. There are limited data regarding treatment of these tumors in the adjuvant and recurrent settings, as they are rare. Identification of ERA and/or GPER positivity, which has been associated with advanced disease and poorer outcomes in other gynecologic cancers, may potentially add prognostic information for patients with uterine AS. The aim of this study was to analyze the differential ER status, including ER>, ERA, and GPER, as well as PgR status in uterine AS.
MATERIALS AND METHODS
From the period of August 2001 to November 2013, 11 patients with histologic diagnoses of uterine AS were identified in our multicampus, single-institution (Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY) database. The Montefiore Office of Research/Institutional Review Board approved the study, and clinical data were abstracted from the medical records. All tumors histologically identified as uterine AS, including those with sarcomatous overgrowth and heterologous elements, were included. Patients at all stages of disease were included in this study. In 1 case, tissue samples were obtained from both the initial tumor and a recurrent tumor several years later. Not all patients underwent hysterectomy at our institution. The only cases excluded were those without sufficient tissue available for further immunohistochemical evaluation.
Paraffin-embedded and formalin-fixed tissue blocks were sectioned at 4-Km thickness and stained by hematoxylin-eosin (H&E stain). They were reviewed by a gynecologic pathologist (R.G.K.) to confirm adequate quantity of tumor sample for immunohistochemical workup. Tumors were classified as AS if the sarcomatous component displayed a monotonous tumor cell population with low-grade nuclei, low mitotic activity, and absence of necrosis. The AS + SO was characterized by pure sarcoma comprising more than 25% of the tumor tissue. Tumors that did not fit the criterion for AS + SO were classified as AS with high-grade features, if marked nuclear pleomorphism, increased mitotic activity including the presence of atypical mitoses, necrosis, and/or heterologous elements were present. Heterologous elements were defined as those composed of osteosarcoma, chondrosarcoma, or rhabdomyosarcoma components. Once the histologic diagnosis was confirmed, representative tumor tissue sections were stained for ER> (clone 1D5; Dako North America, Carpinteria, CA), ERA (clone 14C8; GeneTex, San Antonio, TX), and PgR (clone PgR 636; Dako North America) utilizing standard immunohistochemistry protocols as previously described. 21 Staining for GPER, utilizing a rabbit polyclonal affinity-purified antibody directed against the C-terminus, was performed by our collaborators at the University of New Mexico Health Sciences as previously described. 22 The immunostained tumor sections were then examined for the percentage of overall cells stained and intensity of antibody staining by the study pathologist (R.G.K.). The staining intensity was scored as weak, moderate, or strong. The product of these 2 values was then used to calculate the H score.
Descriptive statistics were calculated using clinicopathologic data abstracted from the medical records. Unpaired t test was used to compare the mean H scores of receptor expression between AS and AS + SO/AS with high-grade features. Analyses were performed with Stata version 13.1 (StataCorp, College Station, TX), as well as GraphPad Prism version 6 (GraphPad Software Inc, San Diego, CA).
RESULTS
Over a 12-year period, 11 patients were diagnosed as having uterine AS at our institution, and clinical staging information was available for 10 of these patients. The demographic and clinical characteristics are described in Table 1 . There were 8 cases of AS and 3 cases of AS with high-grade features. Of the cases with high-grade features, 2 displayed sarcomatous overgrowth, and of those, 1 case contained heterologous elements. One case bordered on sarcomatous overgrowth with high-grade cytomorphology. The mean body mass index was 34.5 kg/m 2 , meeting the Institute of Medicine class I obesity definition. All patients were parous and had at least 1 delivery, with a range of 1 to 12 deliveries. Most patients were menopausal (80%) and presented with postmenopausal bleeding (70%). Specimens obtained were from surgical resection; 10 patients underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy, and only 1 patient underwent limited surgery (dilation and curettage). Most patients presented with stage I disease. Breakdown of stage based on the FIGO 2009 staging system was as follows: 9 (90%) stage I and 1 (10%) stage III. One patient underwent chemotherapy, and 3 received radiation as adjuvant treatment. Three patients had a recurrence, including 1 patient who had a recurrence twice, and the specimen from the first recurrence was evaluable for staining and analysis.
The hormone receptor profile of each tumor sample is described in Table 2 . In AS, 7 of 8 tumor samples showed moderate or strong intensity immunostaining for ER>. In contrast, all tumors with high-grade features (both AS + SO and the sample with high-grade cytomorphology) showed minimal to no ER> immunoreactivity. Immunostained tumor sections are shown in Figure 1 . As summarized in Figure 2 , there was a significant decrease with respect to ER> H scores in those with high-grade features (P = 0.01). Relative to ER>, the PgR immunostaining intensity showed greater variability among tumor samples; however, significantly lower PgR H scores were observed in tumors with high-grade features (P = 0.04, Fig. 2) . In 1 patient with AS + SO and recurrent disease after 2 years, the recurrent tumor remained negative for ER> and PgR. Results of immunostains for ERs ERA and GPER were similar across all samples. Estrogen receptor A immunostaining was variable with respect to percentage of cells staining, but was detectable in all tumor samples except in 1 case. In that outlier case (patient 5), immunostaining was undetectable for all of the hormone receptors. Immunostaining for GPER was absent in the majority of tumor samples, although 3 samples (2 AS, 1 AS + SO with heterologous elements) showed moderate to strong staining.
DISCUSSION
To our knowledge, this is the first study to comprehensively evaluate the female sex hormone receptor profile in uterine ASs. In this study, AS with high-grade features (with or without sarcomatous overgrowth) demonstrated loss of ER> and PgR expression. The decreased expression of ER> and PgR in this group was statistically significant, despite the small sample size, and is consistent with a previous study. A multi-institutional study examining ER/PgR expression has found 85% positivity for ER and 80% positivity for PgR in AS without sarcomatous overgrowth. Those with sarcomatous overgrowth were ER positive in 50% and PgR positive in 25% of cases. There was also less staining reported in the sarcomatous components of both tumors with and without sarcomatous overgrowth. 9 A subsequent analysis evaluated ER/PgR immunostaining in AS with and without SO. The AS + SO tumors displayed a median ER labeling index of less than 5%, whereas 1  AS  IA  3  98 294  3  98 294  0  0  0  3  98 294  2  AS  IA  3  90 270  2  90 180  0  0  0  3  90 270  3  AS  IA  3  95 285  1  5  5  0  0  0  3  80 240  4  AS  IA  3  90 270  1  35  35  0  0  0  3  80 240  5  AS  IB  0  0  0  0  0  0  0  0  0  0  0  0  6  AS  IA  3  75 225  1  10  10  2  30  60  3  95 285  7  AS  IA  2  50 100  1  40  40  0  0  0  3  60 180  8  AS  Unstaged  3  60 180  1  10  10  3  80 240  0  0  0  9  AS with  high-grade  cytomorphology   IB  0  0  0  1  15  15  0  0  0  2  5  10   10  AS + SO  IA  1  5  5  2  40  80  2  15  30  3  15  45  11  AS + SO  IIIA  0  0  0  2  95 190  0  0  0  0  0  0  AS + SO  Recurrence  0  0  0  1  30  30  0  0  0  0  0  0 diffuse ER expression of greater than 80% was seen in those without sarcomatous overgrowth. Similarly, PgR positivity was less frequently observed in tumors with AS + SO than in those without (20% vs 980%). 10 We noted that the hormone receptor profile of the case with high-grade cytomorphology closely resembled AS + SO, suggesting the biology of tumors with highgrade cytomorphology may be more similar to those with sarcomatous overgrowth than those without. According to one of the previous studies of uterine carcinosarcoma, increased expression of ERA and GPER in the glandular component of these higher-grade tumors was associated with advanced-stage disease. 16 However, our study showed similar levels of ERA expression in uterine AS. No significant differences in GPER expression were detected between AS versus AS + SO. G proteinYcoupled estrogen receptor expression was detected in AS + SO tumor that also contained heterologous elements, but not in the remaining 2 samples with high-grade features. As there was only 1 patient with a tumor containing heterologous elements and positive staining for GPER, limited conclusions can be drawn. We found that the GPER expression and ERA expression were not significantly linked to histologic subtype, suggesting that these receptors are not drivers of the more aggressive behavior of ASs with high-grade features or sarcomatous overgrowth.
Limited to smaller studies and case series, the literature has shown an overall favorable prognosis in patients with early-stage uterine AS, with 5-year overall survival of approximating 83% to 84%.
6Y8 Those with deeply myoinvasive disease, stage IB or greater, had a lower rate of survival, ranging from 63% to 69%. The majority of patients with metastatic disease outside the uterus fare poorly, with 0% to 50% survival rates. 6, 8 In our study, we had a limited number of patients with AS + SO. A multi-institutional study looking at treatment outcomes found patients whose tumors exhibited sarcomatous overgrowth were more likely to have a recurrence, although this did not reach statistical significance. Of those with AS + SO who received adjuvant treatment, patients undergoing radiation therapy did not experience any recurrences within the treatment field, and of those who experienced distant recurrences, they were most common in the lung. 8 Additional investigators have found few responses to sarcoma-based treatment and even more limited responses to hormone-based therapies, although ER/PgR tumor status was not consistently known for all patients. 7 In this study, the comprehensive ER profiling is novel and contributes new insights into this rare tumor subtype. The major limitation to this study is the small sample size, with even fewer tumors exhibiting high-grade features, limiting our hypothesized detection of differential hormone receptor expression among AS and AS + SO. Future larger studies with the inclusion of a cohort of cases, particularly those containing sarcomatous overgrowth and/or heterologous elements, could potentially increase the detection of hormone receptor differences among AS subtypes and help to gain further insights into the biology of this tumor.
